Discusses a new subcutaneous initiation dosing option for an anti-amyloid Alzheimer's antibody, emphasizing delivery method, monitoring, and safety considerations.
Key Takeaways
- FDA approved a once-weekly subcutaneous initiation dosing option for lecanemab
- ARIA occurred in 21% with treatment versus 9% with placebo, including 13% ARIA-E
- Severe ARIA rates were highest in ApoE4 homozygotes, notably 13.5% for ARIA-H